SELLAS Life Sciences (SLS)

• Market cap: $2.54B
• 1 day: 3.37%
• 5 days: -2.71%
• 1 month: 51.23%
• 3 months: 156.46%
• 6 months: 181.66%
• Year to date: 196.55%
• 1 year: 597.3%
• 5 years: 38.71%
• 10 years: -99.91%
• Sector: Healthcare
• Industry: Biotechnology

About: SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Employees: 13